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An 84-year-old man reported several episodes of palpitations over the previous 6 months. He had a
history of a prior non-Q-wave myocardial infarction (MI) and had received a dual-chamber pacemaker
for control of subsequent sick sinus syndrome. Pacemaker data revealed 8000 premature ventricular
beats (PVBs) daily and nonsustained ventricular tachycardia (NSVT).
The patient agreed to add omega-3 fatty acid ethyl ester supplementation (1 g/day) to his treatment
regimen. Pacemaker analyses 3 months later demonstrated no NSVT and only 215 PVBs daily. In more
than 1 year of follow-up, the patient has remained well and has had no further ventricular arrhythmias.
We conclude that omega-3 fatty acid ethyl ester supplementation may be beneﬁcial in post-MI patients
with pacemakers who develop ventricular arrhythmias.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The management of patients with ischemic ventricular arrhyth-
mias is complex and may consist of one or more of the following
treatment options: placement of an implantable cardioverter
deﬁbrillator (ICD), use of radiofrequency ablation, and/or prescrip-
tion of conventional antiarrhythmic drugs. The basis of treatment
is technically challenging and may be associated with signiﬁcant
procedural risks. In this report, we present a case that illustrates
the potential role of omega-3 fatty acid ethyl ester supplementa-
tion in the management of these difﬁcult-to-treat patients.2. Case report
During a routine follow-up evaluation in December 2011, an
84-year-old man reported that he had experienced several epi-
sodes of palpitations over the previous 6 months, without asso-
ciated symptoms of vertigo, presyncope, syncope, or angina.
The patient had previously experienced a non-Q-wave myo-
cardial infarction (MI) in 2005. At the time, he had not been taking
his prescribed medications regularly. He reported that he had been
previously well and that he enjoyed strenuous physical activity,
particularly hunting. He was referred to our clinic 2 years after thet Rhythm Society. Published by Els
Arrhythmia Service, Federal
gency of Russia, 28 Orekcho-
ation. Tel.: +7 495 3445792;
v).MI when he was diagnosed with sick sinus syndrome while being
medically managed with a beta blocker (bisoprolol), aspirin, and
an angiotensin-converting enzyme (ACE) inhibitor (perindopril).
To treat his condition, we implanted an ALTRUA dual-chamber
pacemaker (DDDR; Boston Scientiﬁc, MN, USA).
Analysis of the data in the pacemaker memory in December
2011 did not indicate any malfunction and showed that
approximately 8000 premature ventricular beats (PVBs) and
non-sustained ventricular tachycardia (NSVT) were occurring daily
(Fig. 1). According to the patient's diary, the episodes of NSVT and
PVBs coincided with his symptoms. Furthermore, the results of 24-
h Holter monitoring corresponded with the pacemaker data. At
this time, his body mass index (BMI) was 26.
Echocardiography revealed a near-normal size of the left
ventricular chamber, with preserved global systolic function. The
patient's functional class, as rated by the New York Heart Associa-
tion Functional Classiﬁcation (NYHA-FC), was I–II. When we
discussed his diet with him, we found that he typically ate less
than 1 portion of oily ﬁsh per week.
The patient refused to undergo any interventional procedures
(e.g. angiography or an electrophysiologic study) to evaluate the
status of his coronary artery disease and to assess the possible
need for upgrading his ICD. According to current guidelines [1]
and in view of his poor dietary intake of polyunsaturated fatty
acids (PUFAs), he agreed to add an omega-3 fatty acid ethyl ester
supplement (Omacor, known as Lovaza in the US [1 g/day], Abbott
Russia LLC) to his treatment regimen.
When the patient returned for his follow-up appointment
3 months later in March 2012, he noted that he felt well and thatevier B.V. All rights reserved.
Fig. 1. Episodes of nonsustained ventricular tachycardia (3 separate channels of Holter monitoring).
Fig. 2. Frequency of ventricular events. (A) (a) Ventricular events, (b) P-wave amplitude, (c) A-pace impedance, (d) R-wave of Vamplitude, and (e) V-pace impedance from the
pacemaker memory (June 19, 2012) illustrates the positive inﬂuence of Omacor intake (A, atrial events; V, ventricular events). (B) Graph of the number of premature
ventricular beats (PVBs).
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monitoring performed in May 2012 demonstrated no NSVT and
showed only 215 PVBs daily.
Since he began taking omega-3 fatty acid ethyl ester supple-
mentation, the patient has remained well. At a follow-up review in
of June 2012, he conﬁrmed that he continues to be physically
active and to enjoy hunting. He currently takes Omacor (1 g/day),
statins, and aspirin, but he refuses to take beta blockers and ACE
inhibitors. Importantly, he has experienced no further episodes of
ventricular arrhythmias (Fig. 2); therefore, radiofrequency ablation
or ICD placement has not yet been required.3. Discussion
Fish oil derivatives may protect against sudden cardiac death
[2]. The Gruppo Italiano per lo Studio della Sopravvivenza nell'In-
farto Miocardico (GISSI-Prevention) Study of 11,324 patients who
had survived a recent MI demonstrated a highly signiﬁcant (45%)
reduction in risk of sudden cardiac death in the group that
received omega-3 fatty acid ethyl ester supplementation with
Omacor [3]. The reduction in the rate of death caused by cardiac
events was signiﬁcant by month 4 (p¼0.048) [4].
The effect of high-dose omega-3 fatty acids has been examined
in 3 randomized controlled trials that focused speciﬁcally on
ventricular arrhythmias in patients with ICDs for secondary pre-
vention of MI [5–7]. The results of these 3 studies were incon-
sistent. The Study on Omega-3 Fatty Acids and Ventricular
Arrhythmia (SOFA; n¼546) reported a non-signiﬁcant trend
toward event-free survival in a subgroup with prior MI rando-
mized to 2 g of ﬁsh oil per day (Table 1) [5,8]. In the Fatty Acid
Antiarrhythmia Trial (FAAT; n¼402), the use of omega-3 fatty
acids was associated with a signiﬁcant extension (33%) of the time
until the ﬁrst use of ICD or death [6]. However, the third trial of
200 patients who received an ICD because of sustained ventricular
tachycardia or ventricular ﬁbrillation (and not after an MI) failed to
show a reduction in episodes of ventricular tachyarrhythmia after
routine supplementation with omega-3 fatty acids [7]. As sug-
gested by the authors of a recent meta-analysis, the discrepancies
in results among these 3 trials may be due to the use of different
antiarrhythmic medications and/or due to the different interac-
tions of these antiarrhythmic drugs with the omega-3 fatty acids.
There was also heterogeneity among the study populations [9].
Three possible mechanisms may underlie the decrease in the
number of PVBs in the present patient: the ﬁrst is the antiar-
rhythmic action of Omacor, the second is the natural time course
of PVBs, and the third is the day-to-day variability in the number
of PVBs. Therefore, we performed an additional evaluation in
February2013. Based on the device interrogation data, which
demonstrated that the total number of PVBs ranged from 400 toTable 1
A comparison of studies of ﬁsh oils in the prevention of ventricular arrhythmias in
patients with an implantable cardioverter deﬁbrillator (ICD).
Updated from [15].
Study
(Reference)
No. of
patients
Follow-up
duration
(months)
Daily
dose
(g)
Event rate p
Value
Fish oil
group
(%)
Control
group
(%)
SOFA [5] 546 12 2 30 33 0.33
FAAT [6] 402 12 4 28 39 0.057
Raitt et al.
[7]
200 24 1.8 65 59 0.19
FAAT¼Fatty Acid Antiarrhythmia Trial; SOFA¼Study on Omega-3 Fatty Acids and
Ventricular Arrhythmia.2000 per month since March 2012 until recently, we believe that
day-to-day variability of PVBs is the least likely reason for the
decreased number of PVBs. Previous device testing (from June
2011 to Jan 2012) had shown up to 50,000 PVBs per month.
Data regarding the surrogate antiarrhythmogenic effect of
PUFAs are currently rather controversial. Preliminary results from
a pilot study showed that a single intravenous administration of
3.8 g of omega-3 marine triglycerides resulted in decreased
induction of sustained ventricular tachycardia following pro-
grammed stimulation in 5 of 7 ischemic patients with inducible
ventricular tachycardia [10]. A larger study involving 98 patients
with ICDs and ischemic heart disease showed that higher plasma
levels of n-3-PUFAs are associated with a lower incidence of
ventricular arrhythmias [11].
Several studies have shown that omega-3 fatty acids utilize
multiple antiarrhythmic mechanisms, including the inhibition of
calcium overload by maintenance of L-type calcium channels
during cellular stress, high activity of cardiac microsomal calcium
ion–magnesium ion-adenosine triphosphate synthase (Ca2+/Mg2
+-ATPase), and potent inhibition of voltage-gated sodium channels
[12–14].
The present patient had a history of a prior non-Q-wave MI,
episodes of mildly symptomatic NSVT, and preserved global
systolic function of LV; he therefore corresponds to the GISSI-P
trial proﬁle. It is unclear whether the patient's arrhythmia was
linked strictly to his prior MI and/or transient myocardial ischemia
because he refused to undergo electrophysiologic study and
angiography. We did not want to discontinue his treatment with
Omacor and re-challenge him to conﬁrm the efﬁcacy of omega-3
fatty acids in this particular case. Therefore, the omega-3 index
before and after treatment was not evaluated for this patient.4. Conclusions
In the present case, there was a clear positive association
between the commencement of treatment with Omacor and the
cessation of palpitations, although any link must be considered
speculative. The observed dramatic beneﬁt has been sustained
over 12 months of follow-up, in the absence of beta-blocker or
ACE-inhibitor therapies, suggesting a genuine effect of Omacor.
Therefore, we suggest that non-invasive omega-3 fatty acid ethyl
ester supplementation with Omacor may be of beneﬁt in post-MI
patients with ICDs who develop ventricular arrhythmias.Acknowledgments and funding
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